{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:47:47Z","timestamp":1792676867348,"version":"4.5.0"},"reference-count":207,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002397","name":"Shanghai University of Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.phrs.2025.108054","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:52:58Z","timestamp":1764694378000},"page":"108054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights"],"prefix":"10.1016","volume":"222","author":[{"given":"Yibing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186418","article-title":"Fat, fibrosis, and the future: navigating the maze of MASLD\/MASH","volume":"135","author":"Friedman","year":"2025","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.108054_bib3","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib5","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cmet.2024.05.003","article-title":"Metabolic reprogramming in liver fibrosis","volume":"36","author":"Horn","year":"2024","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","article-title":"An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH","volume":"79","author":"Tacke","year":"2023","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/toxins14120833","article-title":"MC-LR aggravates liver lipid metabolism disorders in obese mice fed a high-fat diet via PI3K\/AKT\/mTOR\/SREBP1 signaling pathway","volume":"14","author":"Chu","year":"2022","journal-title":"Toxins"},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.phrs.2025.108054_bib10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/dom.14946","article-title":"A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.phrs.2025.108054_bib14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jcmgh.2021.08.019","article-title":"Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK\/STAT pathway","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.phrs.2025.108054_bib16","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2025.108054_bib17","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood.V87.8.3151.bloodjournal8783151","article-title":"Murine JAK3 is preferentially expressed in hematopoietic tissues and lymphocyte precursor cells","volume":"87","author":"Gurniak","year":"1996","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.phrs.2025.108054_bib18","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41556-024-01429-4","article-title":"Mitochondria and cell death","volume":"26","author":"Glover","year":"2024","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s44321-023-00011-z","article-title":"Mediators of necroptosis: from cell death to metabolic regulation","volume":"16","author":"Wu","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.phrs.2025.108054_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100705","article-title":"There's more to death than life: noncatalytic functions in kinase and pseudokinase signaling","volume":"296","author":"Mace","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/BJ20131174","article-title":"A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties","volume":"457","author":"Murphy","year":"2014","journal-title":"Biochem J."},{"issue":"6702","key":"10.1016\/j.phrs.2025.108054_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.phrs.2025.108054_bib23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase iib randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheuma"},{"issue":"11","key":"10.1016\/j.phrs.2025.108054_bib24","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.7150\/thno.71400","article-title":"Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation","volume":"12","author":"Guo","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib25","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jhep.2020.03.023","article-title":"MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis","volume":"73","author":"Wu","year":"2020","journal-title":"J. Hepatol."},{"issue":"6715","key":"10.1016\/j.phrs.2025.108054_bib26","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.chembiol.2010.05.011","article-title":"Targeting the undruggable proteome: the small molecules of my dreams","volume":"17","author":"Crews","year":"2010","journal-title":"Chem. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108054_bib29","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1021\/acs.jmedchem.0c00339","article-title":"Degradation versus inhibition: development of proteolysis-targeting chimeras for overcoming statin-induced compensatory upregulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase","volume":"63","author":"Li","year":"2020","journal-title":"J. Med Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"issue":"57","key":"10.1016\/j.phrs.2025.108054_bib31","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1038\/onc.2008.320","article-title":"Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer","volume":"27","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2025.108054_bib33","doi-asserted-by":"crossref","DOI":"10.2174\/0109298673384371250806104406","article-title":"PROTACs targeting molecular targets in triple-negative breast cancer","author":"Khan","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108054_bib34","article-title":"Exploiting E3 ligases for lung cancer therapy: the promise of DCAF-PROTACs","volume":"270","author":"Hussain","year":"2025","journal-title":"Pathol. Res. Pr."},{"issue":"14","key":"10.1016\/j.phrs.2025.108054_bib35","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1080\/17568919.2025.2533113","article-title":"Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment","volume":"17","author":"Hussain","year":"2025","journal-title":"Future Med. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2025.108054_bib37","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/j.ymthe.2023.06.016","article-title":"Genetic and pharmacological inhibition of GRPR protects against acute kidney injury via attenuating renal inflammation and necroptosis","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2025.108054_bib38","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1007\/s12035-023-03407-7","article-title":"IRAK-M ablation promotes status epilepticus-induced neuroinflammation via activating M1 microglia and impairing excitatory synaptic function","volume":"60","author":"Liang","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2025.108054_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj3340297","article-title":"Interleukin-6-type cytokine signalling through the gp130\/Jak\/STAT pathway","volume":"334","author":"Heinrich","year":"1998","journal-title":"Biochem J."},{"key":"10.1016\/j.phrs.2025.108054_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2024.101072","article-title":"Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target","volume":"95","author":"Virtanen","year":"2025","journal-title":"Adv. Biol. Regul."},{"issue":"15","key":"10.1016\/j.phrs.2025.108054_bib41","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1073\/pnas.1423201112","article-title":"ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation","volume":"112","author":"Hammar\u00e9n","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6589","key":"10.1016\/j.phrs.2025.108054_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/cdd.2015.70","article-title":"Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis","volume":"23","author":"Rodriguez","year":"2016","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib44","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002113R","article-title":"Systemic Jak1 activation provokes hepatic inflammation and imbalanced FGF23 production and cleavage","volume":"35","author":"Daryadel","year":"2021","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20080003","article-title":"Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation","volume":"206","author":"Hosui","year":"2009","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib46","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/hep.23469","article-title":"Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis","volume":"51","author":"Blaas","year":"2010","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib47","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bbadis.2013.02.019","article-title":"Origins and functions of liver myofibroblasts","volume":"1832","author":"Lemoinne","year":"2013","journal-title":"Biochim Biophys. Acta"},{"issue":"5","key":"10.1016\/j.phrs.2025.108054_bib48","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12967-025-06155-5","article-title":"IFN-\u03b3-mediated inhibition of JAK\/STAT signaling via nano-scutellarin treatment is an efficient strategy for ameliorating liver fibrosis","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2025.108054_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhazmat.2023.132917","article-title":"Scutellarin targets Wnt5a against zearalenone-induced apoptosis in mouse granulosa cells in vitro and in vivo","volume":"464","author":"Sun","year":"2024","journal-title":"J. Hazard Mater."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib51","doi-asserted-by":"crossref","first-page":"18472","DOI":"10.1038\/s41598-025-03411-y","article-title":"Scutellarin suppresses ovarian cancer progression by targeting METTL5","volume":"15","author":"Ding","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10565-024-09956-4","article-title":"Investigating the role of Wnt3a and Wnt5a as critical factors of hepatic stellate cell activation in acute toxicant-induced liver injury","volume":"41","author":"Rutt","year":"2024","journal-title":"Cell Biol. Toxicol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13287-025-04353-y","article-title":"Bone marrow mesenchymal stem cells alleviate liver fibrosis after rat liver transplantation through JAK1\/STAT5 pathway","volume":"16","author":"Si","year":"2025","journal-title":"Stem Cell Res. Ther."},{"issue":"15","key":"10.1016\/j.phrs.2025.108054_bib54","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.2169\/internalmedicine.4723-24","article-title":"A case of severe hypocalcemia during JAK1\/2 inhibitor therapy for myelofibrosis in a patient with liver cirrhosis","volume":"64","author":"Kurumazaki","year":"2025","journal-title":"Intern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2007-03-082941","article-title":"The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-beta-induced inhibitory signaling","volume":"111","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib56","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/1744666X.2022.2042254","article-title":"Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis","volume":"18","author":"Garufi","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib57","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib58","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41589-022-01098-0","article-title":"Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine","volume":"18","author":"Kavanagh","year":"2022","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/jcph.1050","article-title":"Pharmacokinetics and safety of momelotinib in subjects with hepatic or renal impairment","volume":"58","author":"Xin","year":"2018","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2025.108054_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129838","article-title":"Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities","volume":"109","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib61","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/hep.31752","article-title":"Hexa Histidine-Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species","volume":"73","author":"Dat","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib62","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib63","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase","volume":"21","author":"Shan","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"24","key":"10.1016\/j.phrs.2025.108054_bib64","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1002\/cncr.35559","article-title":"New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms","volume":"130","author":"Zhang","year":"2024","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.phrs.2025.108054_bib65","doi-asserted-by":"crossref","first-page":"12567","DOI":"10.1074\/jbc.273.20.12567","article-title":"Jak2-Stat5 interactions analyzed in yeast","volume":"273","author":"Barahmand-Pour","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s12964-024-01841-1","article-title":"STAT3 blockade ameliorates LPS-induced kidney injury through macrophage-driven inflammation","volume":"22","author":"Lee","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib67","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1038\/s41467-024-47684-9","article-title":"AZGP1 in POMC neurons modulates energy homeostasis and metabolism through leptin-mediated STAT3 phosphorylation","volume":"15","author":"Qiu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108054_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2024.109748","article-title":"Leptin limits hepatic lipid accumulation and inflammation via vagal activation of the JAK2-STAT3\/AMPK pathway","volume":"134","author":"Xiong","year":"2024","journal-title":"J. Nutr. Biochem"},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib69","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41418-022-01090-0","article-title":"ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2","volume":"30","author":"Cao","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2025.108054_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154823","article-title":"Suppressor of cytokine signalling-2 controls hepatic gluconeogenesis and hyperglycemia by modulating JAK2\/STAT5 signalling pathway","volume":"122","author":"Zhang","year":"2021","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s12967-022-03692-1","article-title":"The p-STAT3\/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis","volume":"20","author":"Feng","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2025.108054_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106897","article-title":"Kupffer cell depletion attenuates IL-6\/STAT3 mediates hepatocyte apoptosis in immunological liver injury of trichloroethylene sensitized mice","volume":"88","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib73","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib74","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2023.10.025","article-title":"CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis","volume":"80","author":"Lei","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.108054_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170422","article-title":"Chemerin\/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway","volume":"135","author":"An","year":"2021","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2025.108054_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101626","article-title":"NIK\/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2\/STAT5 inhibition","volume":"66","author":"Vesting","year":"2022","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib77","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12967-022-03366-y","article-title":"Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1\/2","volume":"20","author":"Song","year":"2022","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib78","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.32746","article-title":"Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis","volume":"77","author":"Torres","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib79","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.phrs.2025.108054_bib80","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1080\/14796694.2025.2511562","article-title":"Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis","volume":"21","author":"Masarova","year":"2025","journal-title":"Future Oncol."},{"issue":"14","key":"10.1016\/j.phrs.2025.108054_bib81","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","article-title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","volume":"7","author":"Verstovsek","year":"2023","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib82","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1038\/s41598-019-40425-9","article-title":"Capsaicin protects against cisplatin ototoxicity by changing the STAT3\/STAT1 ratio and activating cannabinoid (CB2) receptors in the cochlea","volume":"9","author":"Bhatta","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.canlet.2013.12.008","article-title":"Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases","volume":"345","author":"Lee","year":"2014","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.phrs.2025.108054_bib84","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/onc.2012.107","article-title":"p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway","volume":"32","author":"Ozenne","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.108054_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.729925","article-title":"IL-6\/STAT3 induced neuron apoptosis in hypoxia by downregulating ATF6 expression","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13020-025-01128-8","article-title":"Ginsenoside Rg5 alleviates hypoxia-induced myocardial apoptosis by targeting STAT3 to promote Tyr705 phosphorylation","volume":"20","author":"Li","year":"2025","journal-title":"Chin. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib87","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12964-020-00603-z","article-title":"Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation","volume":"18","author":"Xu","year":"2020","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41392-020-00290-9","article-title":"STAT3 ameliorates cognitive deficits by positively regulating the expression of NMDARs in a mouse model of FTDP-17","volume":"5","author":"Hong","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"8","key":"10.1016\/j.phrs.2025.108054_bib89","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nri1885","article-title":"Tracking STAT nuclear traffic","volume":"6","author":"Reich","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib90","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s13046-021-02179-z","article-title":"BUB1 drives the occurrence and development of bladder cancer by mediating the STAT3 signaling pathway","volume":"40","author":"Jiang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108054_bib91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(01)02354-7","article-title":"Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation","volume":"495","author":"Schuringa","year":"2001","journal-title":"FEBS Lett."},{"issue":"55","key":"10.1016\/j.phrs.2025.108054_bib92","doi-asserted-by":"crossref","first-page":"7656","DOI":"10.1038\/sj.onc.1210567","article-title":"Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity","volume":"26","author":"Lufei","year":"2007","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.phrs.2025.108054_bib93","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/s12276-024-01298-9","article-title":"STAT3 promotes NLRP3 inflammasome activation by mediating NLRP3 mitochondrial translocation","volume":"56","author":"Luo","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib94","doi-asserted-by":"crossref","first-page":"976","DOI":"10.7150\/thno.63751","article-title":"Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib95","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41388-020-01566-8","article-title":"STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis","volume":"40","author":"Lin","year":"2021","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.phrs.2025.108054_bib96","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.phrs.2025.108054_bib97","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2016.155","article-title":"The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK","volume":"30","author":"Rudolph","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.phrs.2025.108054_bib98","doi-asserted-by":"crossref","first-page":"12085","DOI":"10.1021\/acs.jmedchem.5c00950","article-title":"Discovery of a proteolysis-targeting chimera degrader of JAK2 as a potential therapeutic agent for JAK2-mediated myeloproliferative neoplasms","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib99","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: a review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.phrs.2025.108054_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113884","article-title":"Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms","volume":"156","author":"Ge","year":"2022","journal-title":"Biomed. Pharm."},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib101","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2004-10-4093","article-title":"Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways","volume":"105","author":"Tong","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.phrs.2025.108054_bib102","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2006.09.012","article-title":"Tribbles homolog 2 inactivates C\/EBPalpha and causes acute myelogenous leukemia","volume":"10","author":"Keeshan","year":"2006","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib103","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1097-2765(01)00366-5","article-title":"C\/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4","volume":"8","author":"Wang","year":"2001","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib104","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166731","article-title":"Hepatocyte-specific CCAAT\/enhancer binding protein \u03b1 restricts liver fibrosis progression","volume":"134","author":"Yan","year":"2024","journal-title":"J. Clin. Invest"},{"issue":"11","key":"10.1016\/j.phrs.2025.108054_bib105","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1182\/bloodadvances.2021006277","article-title":"Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes","volume":"6","author":"Stomper","year":"2022","journal-title":"Blood Adv."},{"issue":"47","key":"10.1016\/j.phrs.2025.108054_bib106","doi-asserted-by":"crossref","first-page":"33667","DOI":"10.1074\/jbc.M113.503292","article-title":"Impaired phosphorylation and ubiquitination by p70 S6 kinase (p70S6K) and Smad ubiquitination regulatory factor 1 (Smurf1) promote tribbles homolog 2 (TRIB2) stability and carcinogenic property in liver cancer","volume":"288","author":"Wang","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib107","first-page":"1910","article-title":"TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK\/STAT3 signaling pathway in human chronic myelogenous leukemia K562\/ADM cells","volume":"39","author":"Ma","year":"2018","journal-title":"Oncol. Rep."},{"issue":"8","key":"10.1016\/j.phrs.2025.108054_bib108","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2337\/db23-0195","article-title":"TRIB2-Mediated Modulation of AMPK Promotes Hepatic Insulin Resistance","volume":"73","author":"Wang","year":"2024","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib109","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbrc.2019.01.023","article-title":"Alpha-glucosidase inhibitor 1-Deoxynojirimycin promotes beige remodeling of 3T3-L1 preadipocytes via activating AMPK","volume":"509","author":"Li","year":"2019","journal-title":"Biochem Biophys. Res Commun."},{"issue":"5","key":"10.1016\/j.phrs.2025.108054_bib110","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/liv.14782","article-title":"Tribbles homolog 2 promotes hepatic fibrosis and hepatocarcinogenesis through phosphatase 1A-Mediated stabilization of yes-associated protein","volume":"41","author":"Xiang","year":"2021","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib111","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.molcel.2013.05.013","article-title":"TRIB2 acts downstream of Wnt\/TCF in liver cancer cells to regulate YAP and C\/EBP\u03b1 function","volume":"51","author":"Wang","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2025.108054_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117016","article-title":"Discovery of the first selective and potent PROTAC degrader for the pseudokinase TRIB2","volume":"281","author":"Wen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib113","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"issue":"7611","key":"10.1016\/j.phrs.2025.108054_bib114","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.phrs.2025.108054_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153514","article-title":"Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells","volume":"132","author":"Sellar","year":"2022","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.108054_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107000","article-title":"Molecular glues targeting GSPT1 in cancers: A potent therapy","volume":"143","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib117","article-title":"eRF3b, a biomarker for hepatocellular carcinoma, influences cell cycle and phosphoralation status of 4E-BP1","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib118","first-page":"3602","article-title":"eRF3b-37 inhibits the TGF-\u03b21-induced activation of hepatic stellate cells by regulating cell proliferation, G0\/G1 arrest, apoptosis and migration","volume":"42","author":"Xu","year":"2018","journal-title":"Int J. Mol. Med"},{"issue":"11","key":"10.1016\/j.phrs.2025.108054_bib119","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1039\/D3CB00103B","article-title":"Development of a covalent cereblon-based PROTAC employing a fluorosulfate warhead","volume":"4","author":"Nowak","year":"2023","journal-title":"RSC Chem. Biol."},{"issue":"19","key":"10.1016\/j.phrs.2025.108054_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202423524","article-title":"Targeted Degradation of ZBP1 with Covalent PROTACs for Anti-Inflammatory Treatment of Infections","volume":"64","author":"Huang","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"549","key":"10.1016\/j.phrs.2025.108054_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat7951","article-title":"Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells","volume":"11","author":"Foulkes","year":"2018","journal-title":"Sci. Signal"},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib122","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/08830185.2024.2434058","article-title":"E3 ubiquitin ligase Smurf1 promotes cardiomyocyte pyroptosis by mediating ubiquitin-dependent degradation of TRIB2 in a rat model of heart failure","volume":"44","author":"Liu","year":"2025","journal-title":"Int. Rev. Immunol."},{"issue":"21","key":"10.1016\/j.phrs.2025.108054_bib123","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","article-title":"In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112195","article-title":"TRIB2 safeguards naive T cell homeostasis during aging","volume":"42","author":"Cao","year":"2023","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.phrs.2025.108054_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112701","article-title":"The critical role of TRIB2 in cancer and therapy resistance","volume":"13","author":"Mayoral-Varo","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib126","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.immuni.2013.06.018","article-title":"The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism","volume":"39","author":"Murphy","year":"2013","journal-title":"Immunity"},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108054_bib127","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","article-title":"Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase","volume":"148","author":"Sun","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molcel.2014.03.003","article-title":"Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3","volume":"54","author":"Wang","year":"2014","journal-title":"Mol. Cell"},{"issue":"42","key":"10.1016\/j.phrs.2025.108054_bib129","doi-asserted-by":"crossref","first-page":"15072","DOI":"10.1073\/pnas.1408987111","article-title":"Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death","volume":"111","author":"Hildebrand","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2025.108054_bib130","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1038\/s41440-024-01814-4","article-title":"Renalase alleviates salt-induced kidney necroptosis and inflammation","volume":"47","author":"Wang","year":"2024","journal-title":"Hypertens. Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib131","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/s41467-023-41724-6","article-title":"A common human MLKL polymorphism confers resistance to negative regulation by phosphorylation","volume":"14","author":"Garnish","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib132","doi-asserted-by":"crossref","first-page":"869","DOI":"10.7150\/ijbs.56152","article-title":"MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway","volume":"17","author":"Zhao","year":"2021","journal-title":"Int J. Biol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib133","doi-asserted-by":"crossref","DOI":"10.1152\/ajplung.00069.2018","article-title":"Ischemia-reperfusion induces death receptor-independent necroptosis via calpain-STAT3 activation in a lung transplant setting","volume":"315","author":"Kim","year":"2018","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.phrs.2025.108054_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155334","article-title":"Loss of long-chain acyl-CoA synthetase 1 promotes hepatocyte death in alcohol-induced steatohepatitis","volume":"138","author":"Dong","year":"2023","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib135","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/jgh.14740","article-title":"Decrease in fat de novo synthesis and chemokine ligand expression in non-alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain-like pseudokinase","volume":"34","author":"Saeed","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib136","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jhep.2019.11.008","article-title":"Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease","volume":"72","author":"Majdi","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib137","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1007\/s11357-025-01553-5","article-title":"Impact of Mlkl or Ripk3 deletion on age-associated liver inflammation, metabolic health, and lifespan","volume":"47","author":"Mohammed","year":"2025","journal-title":"Geroscience"},{"issue":"14","key":"10.1016\/j.phrs.2025.108054_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411313","article-title":"Targeting Endothelial Necroptosis Disrupts Profibrotic Endothelial-Hepatic Stellate Cells Crosstalk to Alleviate Liver Fibrosis in Nonalcoholic Steatohepatitis","volume":"24","author":"Yan","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib139","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41419-023-05615-4","article-title":"Necroptosis of macrophage is a key pathological feature in biliary atresia via GDCA\/S1PR2\/ZBP1\/p-MLKL axis","volume":"14","author":"Yang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib140","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/jgh.16368","article-title":"Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis","volume":"38","author":"Oh","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib141","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.chembiol.2021.03.005","article-title":"The role of reversible and irreversible covalent chemistry in targeted protein degradation","volume":"28","author":"Kiely-Collins","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib142","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41467-025-56648-6","article-title":"A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.phrs.2025.108054_bib143","doi-asserted-by":"crossref","first-page":"15353","DOI":"10.1021\/acs.jmedchem.4c00949","article-title":"Discovery of covalent MLKL PROTAC degraders via optimization of a theophylline derivative ligand for treating necroptosis","volume":"67","author":"Li","year":"2024","journal-title":"J. Med Chem."},{"issue":"19","key":"10.1016\/j.phrs.2025.108054_bib144","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1021\/acs.jmedchem.2c00548","article-title":"Discovery of a new class of uracil derivatives as potential mixed lineage kinase domain-like protein (MLKL) inhibitors","volume":"65","author":"Cui","year":"2022","journal-title":"J. Med Chem."},{"issue":"16","key":"10.1016\/j.phrs.2025.108054_bib145","doi-asserted-by":"crossref","first-page":"11216","DOI":"10.1021\/acs.jmedchem.3c00665","article-title":"PROTACs Targeting MLKL Protect Cells from Necroptosis","volume":"66","author":"Rathje","year":"2023","journal-title":"J. Med Chem."},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib146","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bcp.2010.06.020","article-title":"The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling","volume":"80","author":"Flannery","year":"2010","journal-title":"Biochem Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib147","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/518259","article-title":"IRAK-M is involved in the pathogenesis of early-onset persistent asthma","volume":"80","author":"Balaci","year":"2007","journal-title":"Am. J. Hum. Genet"},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib148","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41419-023-05621-6","article-title":"IRAK-M suppresses the activation of microglial NLRP3 inflammasome and GSDMD-mediated pyroptosis through inhibiting IRAK1 phosphorylation during experimental autoimmune encephalomyelitis","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib149","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/emboj.2013.2","article-title":"IRAK-M mediates Toll-like receptor\/IL-1R-induced NF\u03baB activation and cytokine production","volume":"32","author":"Zhou","year":"2013","journal-title":"Embo J."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneph.2015.175","article-title":"Innate immunity in diabetes and diabetic nephropathy","volume":"12","author":"Wada","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108054_bib151","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108397","article-title":"A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via \u03b17 nicotinic receptors in human macrophages","volume":"9","author":"Maldifassi","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib152","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ymthe.2019.09.019","article-title":"Neutrophils Deficient in Innate Suppressor IRAK-M Enhances Anti-tumor Immune Responses","volume":"28","author":"Zhang","year":"2020","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2025.108054_bib153","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s42255-020-0261-2","article-title":"Fructose stimulated de novo lipogenesis is promoted by inflammation","volume":"2","author":"Todoric","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phrs.2025.108054_bib154","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.freeradbiomed.2023.11.011","article-title":"Protectin D1 inhibits TLR4 signaling pathway to alleviate non-alcoholic steatohepatitis via upregulating IRAK-M","volume":"210","author":"Liu","year":"2024","journal-title":"Free Radic. Biol. Med."},{"issue":"18","key":"10.1016\/j.phrs.2025.108054_bib155","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1021\/acs.jmedchem.0c01125","article-title":"Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase","volume":"63","author":"Degorce","year":"2020","journal-title":"J. Med Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib156","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bmc.2018.01.008","article-title":"Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4","volume":"26","author":"Degorce","year":"2018","journal-title":"Bioorg. Med Chem."},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108054_bib157","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11010-007-9502-x","article-title":"CDK11(p58) protein kinase activity is associated with Bcl-2 down-regulation in pro-apoptosis pathway","volume":"304","author":"Yun","year":"2007","journal-title":"Mol. Cell Biochem"},{"issue":"10","key":"10.1016\/j.phrs.2025.108054_bib158","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/s41419-022-05298-3","article-title":"TrkC-mediated inhibition of DJ-1 degradation is essential for direct regulation of pathogenesis of hepatocellular carcinoma","volume":"13","author":"Kim","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2025.108054_bib159","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbrc.2022.07.093","article-title":"GSG2 promotes tumor growth through regulating cell proliferation in hepatocellular carcinoma","volume":"625","author":"Li","year":"2022","journal-title":"Biochem Biophys. Res Commun."},{"issue":"16","key":"10.1016\/j.phrs.2025.108054_bib160","doi-asserted-by":"crossref","first-page":"14277","DOI":"10.1021\/acs.jmedchem.4c01104","article-title":"Radioactive ADME demonstrates ARV-110's high druggability despite low oral bioavailability","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib161","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.7150\/thno.77041","article-title":"First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod","volume":"13","author":"Starke","year":"2023","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib162","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.240949","article-title":"Assessing Lung Ventilation and Bronchodilator Response in Asthma and Chronic Obstructive Pulmonary Disease with (19)F MRI","volume":"313","author":"Pippard","year":"2024","journal-title":"Radiology"},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib163","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.cell.2025.03.036","article-title":"CD36-mediated endocytosis of proteolysis-targeting chimeras","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib164","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/s41467-020-18565-8","article-title":"CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis","volume":"11","author":"Hao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.108054_bib165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.mie.2023.05.009","article-title":"Monitoring the interactions between N-degrons and N-recognins of the Arg\/N-degron pathway","volume":"686","author":"Kwon","year":"2023","journal-title":"Methods Enzym."},{"issue":"16","key":"10.1016\/j.phrs.2025.108054_bib166","doi-asserted-by":"crossref","first-page":"13666","DOI":"10.1021\/acs.jmedchem.4c00208","article-title":"Distinct amino acid-based protacs target oncogenic kinases for degradation in non-small cell lung cancer (NSCLC)","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib167","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1038\/s41467-025-60107-7","article-title":"Linker-free PROTACs efficiently induce the degradation of oncoproteins","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib168","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.4103\/1673-5374.313049","article-title":"SOCS1\/JAK2\/STAT3 axis regulates early brain injury induced by subarachnoid hemorrhage via inflammatory responses","volume":"16","author":"Wang","year":"2021","journal-title":"Neural Regen. Res"},{"key":"10.1016\/j.phrs.2025.108054_bib169","doi-asserted-by":"crossref","first-page":"1472425","DOI":"10.3389\/fimmu.2024.1472425","article-title":"Repression of JAK2-STAT1 and PD-L1 by CEP-33779 ameliorates the LPS-induced decline in phagocytic activity of alveolar macrophages and mitigates lung injury in mice","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol."},{"issue":"15","key":"10.1016\/j.phrs.2025.108054_bib170","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.7150\/thno.113852","article-title":"Liver-targeted degradation of BRD4 reverses hepatic fibrosis and enhances metabolism in murine models","volume":"15","author":"Yuan","year":"2025","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.phrs.2025.108054_bib171","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2023-331742","article-title":"RNA-based therapies in liver metabolic diseases","volume":"74","author":"Fontanellas","year":"2025","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.phrs.2025.108054_bib172","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202414646","article-title":"TRIM25-mediated INSIG1 ubiquitination promotes MASH progression through reprogramming lipid metabolism","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.phrs.2025.108054_bib173","doi-asserted-by":"crossref","DOI":"10.1039\/D5MD00252D","article-title":"Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH","author":"Sarkar","year":"2025","journal-title":"RSC Med Chem."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib174","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2024.08.029","article-title":"Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression","volume":"82","author":"Xu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phrs.2025.108054_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116978","article-title":"Targeting oncogenic transcriptional factor c-myc by oligonucleotide PROTAC for the treatment of hepatocellular carcinoma","volume":"280","author":"Ai","year":"2024","journal-title":"Eur. J. Med Chem."},{"issue":"Pt A","key":"10.1016\/j.phrs.2025.108054_bib176","article-title":"E3 ubiquitin ligase Siah1 aggravates NAFLD through Scp2 ubiquitination","volume":"124","author":"Zhu","year":"2023","journal-title":"Int Immunopharmacol."},{"issue":"15","key":"10.1016\/j.phrs.2025.108054_bib177","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.7150\/thno.99407","article-title":"p-STAT3-elevated E3 ubiquitin ligase DTX4 confers the stability of HBV cccDNA by ubiquitinating APOBEC3B in liver","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib178","first-page":"338","article-title":"The FN3K-Nrf2 Axis: a novel therapeutic target in cancer metabolism","volume":"8","author":"Alves","year":"2024","journal-title":"EJMO"},{"key":"10.1016\/j.phrs.2025.108054_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100788","article-title":"Modulating undruggable targets to overcome cancer therapy resistance","volume":"60","author":"Passirani","year":"2022","journal-title":"Drug Resist Updat"},{"issue":"10","key":"10.1016\/j.phrs.2025.108054_bib180","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/cancers16101889","article-title":"\u201cOh, dear we are in tribble\u201d: an overview of the oncogenic functions of tribbles 1","volume":"16","author":"Singh","year":"2024","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.phrs.2025.108054_bib181","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.108054_bib182","doi-asserted-by":"crossref","first-page":"1983421","DOI":"10.1155\/2018\/1983421","article-title":"Elevated serum levels of mixed lineage kinase domain-like protein predict survival of patients during intensive care unit treatment","volume":"2018","author":"Vucur","year":"2018","journal-title":"Dis. Markers"},{"key":"10.1016\/j.phrs.2025.108054_bib183","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.2147\/IJGM.S485153","article-title":"Alteration of serum MLKL levels and their association with severity and clinical outcomes in human severe traumatic brain injury: a prospective cohort study","volume":"17","author":"Jin","year":"2024","journal-title":"Int. J. Gen. Med."},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib184","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/infdis\/jiae370","article-title":"Inhibitory immune checkpoints predict 7-day, in-hospital, and 1-Year mortality of internal medicine patients admitted with bacterial sepsis","volume":"231","author":"Mearelli","year":"2025","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2025.108054_bib185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.31557\/APJCP.2021.22.1.267","article-title":"Janus Kinase-2 mutation associated portal vein thrombosis complicating liver cirrhosis and hepatocellular carcinoma","volume":"22","author":"Rabie","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.phrs.2025.108054_bib186","first-page":"105","article-title":"Sodium butyrate inhibits necroptosis by regulating MLKL via E2F1 in intestinal epithelial cells of liver cirrhosis","volume":"13","author":"Zhou","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.phrs.2025.108054_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156796","article-title":"Precision strike strategy for liver diseases trilogy with xiao-chai-hu decoction: a meta-analysis with machine learning","volume":"142","author":"Wang","year":"2025","journal-title":"Phytomedicine"},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib188","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"24","key":"10.1016\/j.phrs.2025.108054_bib189","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib190","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4049\/jimmunol.1601982","article-title":"Immunomodulatory molecule IRAK-M balances macrophage polarization and determines macrophage responses during renal fibrosis","volume":"199","author":"Steiger","year":"2017","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib191","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.4049\/jimmunol.1402377","article-title":"IRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury","volume":"194","author":"Ballinger","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2025.108054_bib192","doi-asserted-by":"crossref","DOI":"10.1093\/database\/baae111","article-title":"ELiAH: the atlas of E3 ligases in human tissues for targeted protein degradation with reduced off-target effect","volume":"2024","author":"Paik","year":"2024","journal-title":"Database"},{"key":"10.1016\/j.phrs.2025.108054_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2024.100737","article-title":"Biomarkers of hepatic toxicity: an overview","volume":"100","author":"Thakur","year":"2024","journal-title":"Curr. Ther. Res Clin. Exp."},{"issue":"6","key":"10.1016\/j.phrs.2025.108054_bib194","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","article-title":"A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation","volume":"54","author":"Vujkovic","year":"2022","journal-title":"Nat. Genet"},{"issue":"12","key":"10.1016\/j.phrs.2025.108054_bib195","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1172\/JCI44213","article-title":"Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice","volume":"120","author":"Burkhardt","year":"2010","journal-title":"J. Clin. Invest"},{"issue":"5","key":"10.1016\/j.phrs.2025.108054_bib196","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jhep.2023.12.029","article-title":"TRIB3-TRIM8 complex drives NAFLD progression by regulating HNF4\u03b1 stability","volume":"80","author":"Xiao","year":"2024","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108054_bib197","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/15548627.2019.1635383","article-title":"Disrupting the TRIB3-SQSTM1 interaction reduces liver fibrosis by restoring autophagy and suppressing exosome-mediated HSC activation","volume":"16","author":"Zhang","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.phrs.2025.108054_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2023.102159","article-title":"Syringin alleviates hepatic fibrosis by enhancing autophagic flux and attenuating ER stress-TRIB3\/SMAD3 in diabetic mice","volume":"83","author":"Deng","year":"2023","journal-title":"Tissue Cell"},{"key":"10.1016\/j.phrs.2025.108054_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138292","article-title":"PROTAC-mediated FTO protein degradation effectively alleviates diet-induced obesity and hepatic steatosis","volume":"285","author":"Xiao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"11","key":"10.1016\/j.phrs.2025.108054_bib200","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1021\/acsmedchemlett.4c00357","article-title":"In Vivo-Active Soluble Epoxide Hydrolase-Targeting PROTACs with Improved Potency and Stability","volume":"15","author":"Nakane","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.phrs.2025.108054_bib201","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.ymthe.2025.02.013","article-title":"A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2025.108054_bib202","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.freeradbiomed.2025.02.042","article-title":"A Keap1-recruiting BRD4 degrader offers a single-molecular polypharmacology approach for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"232","author":"Zhang","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2025.108054_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108626","article-title":"A novel designed fully peptide-based PROTAC, FPP29, demonstrates its potent cytotoxic effects to liver cancer HCCLM3 cells by targeting FOXM1","volume":"163","author":"Jia","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"19","key":"10.1016\/j.phrs.2025.108054_bib204","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","article-title":"Discovery of novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma","volume":"67","author":"Huang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2025.108054_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-JAK-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108054_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116167","article-title":"JAK1\/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.phrs.2025.108054_bib207","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/acsmedchemlett.1c00650","article-title":"Development of potent and selective janus kinase 2\/3 directing PG-PROTACs","volume":"13","author":"Alcock","year":"2022","journal-title":"ACS Med Chem. Lett."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:46:49Z","timestamp":1773852409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":207,"alternative-id":["S1043661825004797"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108054","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteolysis targeting chimera degraders target pseudokinases to treat metabolic dysfunction-associated steatohepatitis and fibrosis: Mechanisms and therapeutic insights","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108054"}}